Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q3 2024 earnings on Nov 5, 2024. The consensus estimate for ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Oppenheimer analyst Justin Kim maintained a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) Inc on Thursday, setting a price target of $62, which is approximately ...